combacte-care Press Release

COMBACTE-CARE: A New Public-Private Funded Project to Combat Carbapenem Resisitance

COMBACTE-CARE: A New Public-Private Funded Project to Combat Carbapenem Resisitance

01/06/2023

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Data support that antibiotic aztreonam -avibactam (ATM-AVI) is effective and well- tolerated in treating infections caused by Gram-negative bacteri...

28/02/2023

Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

Abstract Background: Data on risk factors for carbapenem-resistant Enterobacterales (CRE) with wider applicability are needed to inform preventive me...

13/01/2022

Factors associated with recruitment success in the phase 2a study of aztreonam–avibactam development programme: a descriptive qualitative analysis among sites in Spain

ABSTRACT Objective Successful clinical trials are subject to recruitment. Recently, the REJUVENATE trial, a prospective phase 2a open-label, single-ar...